2009 Top Business Process Outsourcing Vendors, Black Book Survey 2009 Results – Aarkstore Enterprise

The 2009 Black Book of Outsourcing client experience survey investigates a subset of over 3000 Business Process Outsourcing contracts held by 800 corporate buyers of BPO.
18 Key Performance Indicators (KPIs) or criteria are employed specific to BPO buyers within all verticals and sectors, scored on each respective vendor and ranked per KPI.
Key Finding: Most Important Customer Satisfaction KPIs in Cross-Industry BPO Sector
Innovation, customization and reliability are the most important attributes influencing Cross-Industry BPO client satisfaction with their 2009 outsourcing providers. All three KPIs were overwhelmingly praised by the clients of HCL BPO, which captured the overall honors across all verticals and horizontal functionalities this year.
Key Finding: Vendor Dissatisfaction is uncommon in the BPO Industry Outsourcing Sector among Top Tier Ranked Suppliers
Strong dissatisfaction is uncommon among the largest and most comprehensive suppliers of BPO occurring in only 6.5% of financial and accounting clients and 8.8% of transactional services clients.
US clients are among the most satisfied with cross-industry BPO services delivery averaging 95.5% with 2009 projects delivered from North American based suppliers (US, Canada and Mexico). Stronger dissatisfaction was more commonly reported from engagements with offshore outsourcing vendors with 13.7% of all surveyed BPO clients (Philippines, India).
Key Finding: Comprehensive Services Vendor arrangements from Full Service BPO Vendors produce the Highest Satisfaction Rates
Vendors offering comprehensive BPO and ITO Services ranked highest in the overall survey by all clients. Cross industry clients showed significant preference for vendors who are capable of offering more extensive service lines once satisfied with initial projects.
HCL BPO compiled the highest rankings and client experience scores across three of the four major functional subdivisions of BPO services this year.

Companies Mentioned

HCL BPO, Convergys, TCS BPO, Quattro BPO, IBM Global, Aegis, EXL Service, Syntel, Firstsource, Transworks BPO, WNS Global, Genpact, Infosys, Interglobe IGT, Perot Systems, Softtek, Vertex, EDS, Wipro BPO, Caliber Point,

More Information:
http://www.aarkstore.com/reports/2009-Top-Business-Process-Outsourcing-Vendors-Black-Book-Survey-2009-Results-31079.html

The role of smart enabler: supply-side case studies

This is the third in a series of reports examining the potential and risk of the smart enabler role. In our first and second reports, The role of smart enabler: positioning for growth in the open mobile market and The role of smart enabler: the framework unwrapped, we created a smart enabler framework and examined the enablers which are being developed. In this report we provide an overview of the vendors providing solutions in the smart enabler market.
 
 
Table of Contents : 
Executive summary
In a nutshell
Key messages
The smart enabler role is complex
There are significant risks for specialist players
Larger diversified players: lower risks, leverage existing assets
Operators are not the only ‘smart enablers’ in town
Beware the hype
Smart enabler vendors: overview
Case studies
Vendor positioning
Aepona: universal service platform
Player evaluation
Company credentials
Company strategy
The platform is at the heart of its strategy
Expanding platform capabilities
Partners: building momentum with application developers
Operator customers
Business models
Amdocs Interactive app store
Player evaluation
Company credentials
Application store strategy
GetJar
Player evaluation
Company credentials
Company strategy
The GetJar ecosystem
A scalable model
The business model
mBlox: aggregator for the new model
Player evaluation
Company credentials
Company strategy
mBlox solutions
Future services: preparing the way
Ericsson IPX: multimedia brokering
Player evaluation
Company credentials
Company strategy
Ericsson IPX’s customer base
Business models

For more information please visit:
http://www.aarkstore.com/reports/The-role-of-smart-enabler-supply-side-case-studies-31328.html

UK Consumer Insights 2009: Marks & Spencer – Clothing – Aarkstore Enterprise

UK Consumer Insights 2009 are based around individual retailers and provide a highly detailed, data-rich overview of a retailer’s customers, drawing on a nationwide survey of 6,000 shoppers each year.

Reasons to Purchase

*New analysis, unique to these reports shows details about non-converting visitors including where they main shop and who they are.
*Analysis by non-standard demographics is also presented to give a comprehensive picture of a retailer’s customers.
*Key demographics include among others, sex, age, social class, television region, marital status, housing tenure, working status and ACORN group.
 
 
Table of Contents : 
“About the cDNA programme 3

Section 1: At a glance summary 4
- At a glance summary 5

Section 2: Share of shoppers 6
- Marks & Spencer share of shoppers 7
- Marks & Spencer share of shoppers by demographics 8
- Marks & Spencer share of shoppers by television region 9
- Marks & Spencer share of shoppers by household characteristics 10
- Marks & Spencer share of shoppers by other characteristics and ACORN classification 11

Section 3: Conversion and non-conversion 12
- Marks & Spencer conversion of visitors to main users 13
- Marks & Spencer conversion of visitors to main users by demographics and region 14
- Marks & Spencer conversion of visitors to main users by household characteristics 15
- Non-converting customers 16
- Profile of Marks & Spencer non-converting customers by demographics and region 17

Section 4: Shopper profiles 18
- Marks & Spencer profile of shoppers by demographics 19
- Marks & Spencer profile of shoppers by television region 20
- Marks & Spencer profile of shoppers by household characteristics 21
- Marks & Spencer profile of shoppers by other characteristics and ACORN classification 22

Section 5: Loyalty 23
- Marks & Spencer loyalty of main users 24
- Marks & Spencer loyalty of main users by demographics and region 25
- Marks & Spencer loyalty of main users by household characteristics 26
- Marks & Spencer basic drivers of loyalty and disloyalty 27
- Marks & Spencer detailed drivers of loyalty 28

Section 6: Competition 29
- Competition in clothing 30
- Cross sector competitor dynamics 31

Appendix 32
Basic Methodology 33
Detailed Methodology 34″

For More Information Kindly Visit Below Link :
http://www.aarkstore.com/reports/UK-Consumer-Insights-2009-Marks-Spencer-Clothing-15657.html

The Asian Cardiovascular Market Outlook to 2014: Regional and therapeutic analysis, pipeline impact and growth opportunities – Aarkstore Enterprise

The Asian cardiovascular market demonstrated robust sales, unlike the global market which has begun to slow down due to patent expiries of class leading products and strong generic competition. The emerging ten Asian markets analyzed in this report is a mixture of developed nations like South Korea, Taiwan, Hong Kong, Singapore and Malaysia, and developing markets such as China, India, Thailand, Philippines and Indonesia. Although these markets have lower healthcare expenditure per head compared to the US and EU, the Asian markets are regarded as the potential growth markets of the health services industry and consequently the pharmaceutical sector. The market is also being driven by the shift of focus from primary care to specialty care. In comparison to the western markets drug patent expiries minimally affect proprietary brand growth dynamics in Asia. Regional customization of brand prices and aggressive marketing strategies have positioned branded drugs in direct competition with generic brands.

Table of Contents :
Executive Summary
Patient potential
Regional healthcare and licensing trends
Regional market analysis
Key players in the Asian cardiovascular market
Chapter 1 Scope and methodology
Scope
Key CV sub-therapy areas covered in this report
Methodology
Chapter 2 Patient potential
Summary
Introduction
Disease description
Defining patient potential
Limitations of cardiovascular epidemiology data
Cardiovascular risk factors
Hypertension
Dyslipidemia
Diabetes
Cardiovascular disease
Acute thrombotic events
Acute coronary syndrome
Venous thromboembolism
Stroke
Chapter 3 Regional healthcare and licensing trends
Summary
Introduction
Regional healthcare expenditure
Healthcare financing
The external environment
Licensing analysis
Chapter 4 Regional market analysis
Summary
Introduction
Leading cardiovascular therapy areas
Leading Asian cardiovascular markets
Leading cardiovascular brands
Antihypertensives
Introduction
Leading antihypertensive brands
Regional dynamics
Market analysis by drug class
Calcium channel blockers: driven by replacability
Angiotensin receptor blockers: driven by efficacy
ACE inhibitors: downplayed by side effects
Beta-blockers: driven by pricing
Diuretics: outdated and stabilizing
Antihypertensives sales forecasts
Anti-dyslipidemics
Introduction
Leading anti-dyslipidemic brands
Regional dynamics
Market analysis by drug class
Statins: irreplacable dominance
Fibrates: outdated
Other anti-dyslipidemics
Anti-dyslipidemics sales forecast
Cardiac therapies
Introduction
Leading cardiac therapy brands
Market analysis by drug class
Nitrates/nitrites: driven by pricing
Anti-arrhythmics: overcome by nitrates
Others
Cardiac therapies sales forecasts
Anti-thrombotics
Introduction
Leading anti-thrombotic brands
Regional dynamics
Market analysis by drug class
Heparins/low molecular weight heparins: overshadowed by antiplatelets
Vitamin K antagonists: outdated
Oral anti-platelets: preventive advantage drives sales
Fibrinolytics: driven by emergency care demands
Anti-thrombotic sales forecasts
Chapter 5 Key players in the Asian cardiovascular market
Summary
Introduction
Key events and trends
Global CV research affected by ‘Lipitorphobia’; diffused impact on Asia
From a single wheeled to multi-wheeled structure: reducing dependence on the CV sector, target Asia
HDL mimetics will minimally drive the Asian market
Asian market shares
Pfizer: contemplating a paradigm shift
Country focus
Therapy focus
Key brands
Pipeline
Apixaban
Cardiovascular portfolio sales forecasts
Sanofi-Aventis
Country focus
Therapy focus
Key brands
Pipeline
Multaq
Cardiovascular portfolio sales forecasts
AstraZeneca
Country focus
Therapy focus
Key brands
Pipeline
Ticagrelor
Cardiovascular portfolio sales forecasts
Novartis
Country focus
Therapy focus
Key brands
Pipeline
Tekturna
Cardiovascular portfolio sales forecasts
Merck & Co
Country focus
Therapy focus
Key brands
Pipeline
Anacetrapib
Cardiovascular portfolio sales forecasts
Bayer
Country focus
Therapy focus
Key brands
Pipeline: Xarelto to capture Lovenox market
Xarelto
Cardiovascular portfolio sales forecasts
GSK
Country focus
Therapy focus
Key brands
Pipeline
Letairis
Cardiovascular portfolio sales forecasts
Servier
Country focus
Therapy focus
Key brands
Pipeline
Cardiovascular portfolio sales forecasts
Roche
Country focus
Therapy focus
Key brands
Pipeline
Dalcetrapib
Cardiovascular portfolio sales forecasts
Boehringer Ingelheim
Country focus
Therapy focus
Key brands
Pipeline
Cardiovascular portfolio sales forecasts
Forecast rankings of the key players, 2014
Chapter 6 Appendix
IMS Data
C1 Cardiac therapy
C2 Antihypertensives
C3 Diuretics
C4 Cerebral and peripheral vasotherapeutics
C5 Antivaricosis/anti-haemorrhoidal preparations
C6 Other cardiovascular products
C7 Beta-blocking agents
C8 Calcium antagonists
C9 Agents acting on the renin-angiotensin system
C10 Lipid-regulating/anti-atheroma preparations
C11 Cardiovascular multitherapy combination products
B1 Anti-thrombotic agents
B2 Antifibrinolytics, antidotes to anti-coagulants, inhibitors, blood coagulation and haemostyptics
B3 Anti-anaemic preparations
B6 All other haematological agentsGlossary
Glossary
Index

For more information, kindly visit :
http://www.aarkstore.com/reports/The-Asian-Cardiovascular-Market-Outlook-to-2014-Regional-and-therapeutic-analysis-pipeline-impact-and-growth-opportunities-13974.html

The Scandinavian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities – Aarkstore Enterprise

The Scandinavian Pharma Market Outlook to 2013: Policy environment, market structure, pipeline analysis and growth opportunities

The Scandinavian healthcare system and pharmaceutical market is well regulated, with the state bearing responsibility for a large proportion of an individual’s pharmaceutical expenses. Solidarity and equality are the ideological basis of these welfare states, and a significant public commitment exists towards ensuring access to high quality health care for all citizens. Sweden and Denmark have been the two biggest pharma and biotech markets in Scandinavia, while regional players such as Novo Nordisk have laid the foundations for this industry in the region.

‘The Scandinavian Pharmaceutical Market Outlook to 2013’ is a report published explores the healthcare systems and policy environments of Denmark, Norway, Sweden and Finland. This report examines the region’s market potential by assessing historic epidemiological data, sales trends, competitive intelligence and clinical data across each major country. The growth drivers of the region are identified and forecasts for major prescription drugs and markets are provided for the period 2009-13. The competitive landscape of the Scandinavian market is also evaluated, with the region’s five leading companies being assessed based upon their marketed product portfolios and R&D pipelines in order to forecast their future competitive positions.

Key Findings

The Scandinavian pharma market recorded sales of $10.1bn in 2007, a 16% increase over 2006. Sweden had the largest market share (38%), followed by Finland (23%), Denmark (22%), and Norway (17%). These countries possess developed infrastructures, advanced technologies, R&D support and business friendly cultures. Pfizer led the Scandinavian market in 2007 with sales of $696m, a 6.3% increase over 2006.

Pfizer has a significant presence in all four Scandinavian markets and in the leading therapeutic areas of the region. Drugs for the treatment of CNS disorders are the largest product class in Scandinavia, with a market share of 20.7% in 2007. Cancer and cardiovascular diseases are the next largest therapeutic categories in the region.

Well-developed biotech and life sciences clusters across the Scandinavian region enable world-class research and provide pools of well-educated personnel and versatile facilities to support start-up companies.

Parallel trade has become a major concern for the profitability of Scandinavia-based Pharma companies in recent years. Factors driving this include lower prescription drug expenditures sought by payors and parallel traders’ strategies benefit from price differentials for drugs across different countries.

Use this report to…

• Compare the healthcare markets of key Scandinavian countries with this report’s macroeconomic analysis of infrastructure, per capita health expenditure and Pharma sales growth vs. GDP growth across Sweden, Finland, Denmark and Norway.

• Understand how healthcare policy environments vary across the region with this report’s examination of drug approval processes, pricing regulations and reimbursement policies in each major country.

• Identify which indications have the greatest potential to provide franchise growth with this report’s evaluation of major therapy/sub-therapy areas and leading brands, including forecast sales over the period 2009-2013.

• Measure the performances and prospects of leading companies in the Scandanavian area with this report’s strategic analysis of leading pharma corporations based on sales focus by drug class, currently marketed products and R&D pipeline portfolios.

Explore issues including…

The threat to EU health spending. Pharma activity in the Scandinavian market is focused around cost containment, but in recent years the consumption of generics and parallel imports has slowly increased. A new pricing regime linked to other European countries has also had a moderating effect on price levels in Scandinavian countries over recent years.

Higher licensing deal values. Competition for promising projects (particularly drugs that have established solid proof-of-concept data) has not only boosted the deal values overall, but also increased the quantity and average value of deals in the early stages of product development.

Parallel trade influencing pricing. The prevalence of parallel trade is having a significant impact upon state expenditure on drugs and consumer prices. In Sweden, parallel imports have been included as substitutable products in accordance with the generic substitution policy, giving significant boost to parallel imported products in the country.

Support for generic substitution of patented drugs. A report by the National Trade Estimate of the United States Trade Representative (USTR) made special mention of Finland, due to the country’s Pharma Pricing Board not always waiting for the expiry of the analogous process patent before taking action.Discover…

• What will be the major growth drivers in the Scandinavian pharma market over 2009-13?

• Which companies were the winners and losers in the Scandinavian pharma market in 2007?

• Which companies will become key players over 2009 -13?

• Which products will be affected by generic competitors over the period 2009-13?

• Which pipeline products will be the growth drivers of the future?

• Which therapy areas and indications have the highest market potential over 2009-13?

• How will the Scandinavian pharma market’s competitive landscape change by 2013?

 For more information, kindly visit :
http://www.aarkstore.com/reports/The-Scandinavian-Pharmaceutical-Market-Outlook-to-2013-Policy-environment-market-structure-pipeline-analysis-growth-opportunities-13979.html

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors – Aarkstore Enterprise

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors

Large Pharma companies have become heavily dependant upon alliances and in-licensing to gain access to technologies/new molecular entities from Biopharma. This reliance has strengthened Biopharma’s bargaining position, and is reflected in negotiation tactics which aim to expand their role beyond product discovery and development towards an active participation in the the future of their products. This is emphasized by the growing complexity of licensing deals, as Biopharma attempts to secure marketing and commercialization rights within partnership deals.

Furthermore, recent increases in internal Biopharma consolidation are an indicator of the ability of well-established Biopharma companies to effectively compete against traditional big Pharma.

‘Evolving Trends in Biopharmaceutical Licensing’ is a report provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies. The future prospects of the industry are assessed and the potential impact of political/regulatory factors upon licensing and alliances is identified. This report also investigates the influence of the recent upsurge in M&A activity and provides recommendations on the strategies that can sustain future growth.

Key Findings

• Several top-ranked Biopharma companies have matched the consistent sales growth of major traditional pharma companies. A key component of this success has been the increasing reliance of big Pharma to improve R&D productivity and rejuvenate sales of marketed portfolios through licensing and partnership deals.
• Big Pharma has been acquiring Biopharma companies at an increasing rate, resulting in this becoming the fastest-growing M&A sector in 2008 with deal values up 87%. Intense competition and financial uncertainty has also prompted a surge in biopharma consolidation, with 52 biopharma/biopharma deals in 2007.
• Considerable potential for Biopharma licensing deals still exists, particularly within the OAD class of drugs and non-invasive insulin drug delivery technologies.
• The total deal size of early-stage alliances with biopharma has increased six-fold, with total deal values in 2007 estimated at $18bn. This has been driven by the relatively lower costs of discovery and lead development, despite the higher risk of failure.
• Co-development/co-promotion deals accounted for 30% of licensing deals over 2006-07. Licensing deals will continue to become more complex due to biopharma’s desire to remain involved in their product lifecycle beyond the stages of discovery and development

Use this report to…

• Examine the licensing landscape of the biopharma industry with this report’s analysis of Biopharma and Pharma licensing and alliance activity and an examination of specific approaches utilized by both sectors.
• Discover the drivers and challenges facing Biopharma licensing, understand how Biopharma companies are preparing to exploit new opportunities and assess deal-making trends across clinical trials phases and key therapeutic areas.
• Evaluate the strategies of leading companies involved in biopharmaceutical licensing with this report’s analysis of deal activities amongst leading players and identify the changing dynamics of Biopharma/Pharma partnerships.
• Assess the future prospects of the Biopharma industry and how current market and political/regulatory factors will impact the dynamics of licensing and alliances, as well as potential strategies for sustaining growth.

Explore issues including…

• Biopharmas reduced reliance on Pharma. Biopharma is sustaining its efforts to increase its role outside of product development/discovery to become actively engaged in the future of their products. As such, it is becoming increasingly difficult to differentiate big Pharma from major Biopharma companies.
• Optimizing revenue potential. Biopharma are increasingly targeting high value therapy areas, such as oncology and inflammatory disease, bringing them into direct competition with major Pharma.
• Future competitive strategies. With licensing deals increasing in value and complexity, Biopharma companies are looking to increase their involvement by forming long-term, partnership-based relationships. This active engagement in licensing deals will typically involve the negotiation of equity investment and the co-promotion and co-marketing of a drug that allows Biopharma to generate additional downstream revenues.
• Drug development potential. The emergence of several new Biopharma companies with innovative technology platforms has created immense potential for intra-Biopharma licensing trends to continue developing novel drugs that can successfully differentiate themselves within the marketplace.

Discover…

• How will the increasing competition for attractive Biopharma licensing candidates affect deal terms and values?
• How can Biopharma companies improve their licensing strategies to ensure future growth?
• What have been the major trends in licensing agreements between Biopharma and Pharma over 2001-08?
• Which strategies have Biopharma used to reduce their reliance on Pharma?
• How has the value, volume and competition for Biopharma licensing deals changed over 2001-08?
• What have been the strategies of successful Biopharma and Pharma deal-makers?
• Why are Biopharma and Pharma increasingly adopting M&A strategies instead of entering into licensing agreements?

For more information, kindly visit :
http://www.aarkstore.com/reports/Evolving-Trends-in-Biopharmaceutical-Licensing-Deal-assessments-drivers-and-resistors-13949.html

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI – Aarkstore Enterprise

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROIs

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years. They enable companies to focus on core competencies such as drug discovery or technology development whilst contracting out non-core processes to experts, often at lower costs. As offshore investments begin to mature and provide returns on investment, the opportunity to migrate individual components or whole segments of R&D portfolios will continue to rise.

‘Key Trends in Offshoring Pharmaceutical R&D’ is a report published evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities. This report identifies emerging areas of technological and scientific significance across the globe and examines the offshore strategies and investments of the top 20 pharma and biotech companies across Asia, Australia, Central and Eastern Europe, Latin America and the Far East. This report also provides a financial and managerial valuation of leading companies based on their P/E ratio, return on assets (ROA) and return on investment (ROI) and measures company performance against the healthcare industry, pharmaceutical and biotechnology sectors and leading shares of the S&P500.

Key Findings

• Companies that have allocated over 60% of their R&D expenditure offshore have displayed greater shareholder return, operating margins, market capital growth and return on assets.

• The US currently attracts 53% of total industry R&D spend, however it is forecast that 20% of this expenditure will migrate to Asia Pacific by 2010. Australia, China and Singapore are emerging as key areas for scientific and technological investment.

• Leading pharma and biotech companies have undergone major R&D restructuring over the last five years and now adopt a focused, streamlined global approach which is increasingly reliant on offshore strategic partnerships, academic collaboration and outsourcing to establish networks of scientific expertise.

• Scientific and technological excellence within emerging economies is a key incentive for offshore investment, enabling companies to enhance innovation and productivity within their R&D programs.

• Managerial expertise is a critical factor driving the success of offshore investments, helping leading pharma and healthcare companies to outperform their peers and the S&P 500 index in 2008.

Use this report to…

• Assess the offshore R&D strategies of the top 20 pharma and biotech companies with this report’s analysis of offshore investment and deal trends over the last five years.

• Discover which geographic regions have the greatest potential for offshore R&D investment by identifying key areas of technological, scientific and academic expertise across Asia Pacific, Australia, Eastern Europe, Latin America, the Middle East and South Africa.

• Measure how the offshore strategies of the top 20 pharma and biotech companies have influenced their R&D productivity and efficiency with this report’s financial and managerial performance review, comparative analysis of healthcare/pharma/biotech sectors and S&P500 index assessment.

• Identify the key drivers and opportunities for offshore investment with this report’s analysis of major offshoring trends and R&D developments.

Explore issues including…

Shifting focus of R&D strategies. The industry has become more globalized in its R&D approach as part of efforts to improve productivity and efficiency. Networks of offshore partnerships and academic collaborations are now enabling companies to harness external expertise on a project by project basis.

Offshore investment in emerging economies. Companies are increasingly turning to emerging countries to counter the slowing growth of US and European markets. Investing in offshore R&D facilities provides companies with local expertise and a greater understanding of local economies.

Offshore opportunities in tertiary economies. The success of commercial opportunities in emerging markets has expanded the regional scope of investment, with Australia, Israel and Singapore all seen to provide labour arbitrage and access to specialists.

Focused managerial directives are critical. Successful R&D performance is underpinned by a streamlined R&D strategy which is well managed by a team of scientists, technologists and non-scientists which can guide global networks ensuring early go/no go decision making which builds on the core competencies of both internal and external researchers.

Discover…

• Which countries are attracting offshore investment?

• Which areas of research and technology are attracting offshore investment?

• How are the leading pharma and biotech companies changing their R&D programs?

• Which major companies and academic institutions have attracted offshore investment?

• What factors are driving offshore investment?

• What is the financial performance of the leading pharma and biotech companies based on P/E ratio compared to their peers and the S&P500?

• Which companies have delivered the best return on assets and return on investment during the last five years?

• How will offshore investment influence R&D productivity in the future?

 For more information, kindly visit :
http://www.aarkstore.com/reports/Key-Trends-in-Offshoring-Pharmaceutical-R-D-Company-strategies-emerging-markets-and-impact-on-ROI-13950.html

The Future of Software Delivery: The opportunities and challenges of emerging software delivery models – Aarkstore Enterprise

The Future of Software Delivery

The opportunities and challenges of emerging software delivery models

Report Overview

The way companies perceive and purchase their software is starting to change. Organizations no longer have to buy an on-premise application and host it on site, they can have it delivered on-demand, as a service or hosted by the software provider or a third party. But while these new models offer more choice in how they pay, receive and use applications, the proliferation of terms has led to some confusion amongst organizations about what they are and what they constitute. ‘The Future of Software Delivery: The opportunities and challenges of emerging software delivery models’ is a new report published by Business Insights that examines the market conditions that led to the emergence of these new models and the benefits they offer over traditional delivery types. This report also examines future market opportunities for software delivery models and how they may be extended to hardware platforms in the future.

Key Findings

The size of the on-demand CRM market will increase rapidly through 2009 to reach 27% of total market size as the CAGR for on-demand far exceeds that for the total CRM market.

There are signs that enterprises with revenue of more than $1bn are also adopting more SaaS (Software as a Service) applications. Originally some industry commentators predicted SaaS would not expand beyond SMBs into larger organizations.

A study by Triple Tree and the Software and Information Industry Association (SIIA) found that on-demand deployments were 50% to 90% faster, with a total cost of ownership five to ten times less than installed software.

The growth rates for on-demand CRM and ERP application markets are significantly higher than for the premise-based market. This is an indicator of the high levels of growth potential in the market.

Use this report to…

• Identify and target future growth areas of on-demand CRM using this report’s analysis of new market opportunities by sizeband, vertical and region, as well as market forecasts for key sectors.

• Understand the key issues in the software delivery market including vendor ecosystem, competitor offering and on-demand vs on-premise deployments.

• Enhance your sales and marketing strategies with this report’s comparison of different vendor strategies and recommendations on improving your go-to-market strategy. • Assess emerging software delivery models with this report’s cost analysis of implementing software via different models.

Explore issues including…

On-demand is often used interchangeably with SaaS, but it’s also a bigger concept in its own right, referring to a new way for organizations to respond faster to customer demand, build new partnerships or react to market changes.

Vendor ecosystem. At the moment there is no single vendor leading the market for SaaS delivered solutions. Jostling for dominance in this market are traditional applications vendors, infrastructure vendors, pure play SaaS vendors and services providers.

SaaS in the enterprise. SaaS looks set to continue pervading the enterprise, whether through those application areas that suit Internet-based delivery, such as web conferencing and collaboration tools, to those that were previously considered as necessary to be kept behind the firewall: helpdesk, back-up software, word processing, spreadsheets, slideshows, content management and even supply chain management software.

Discover

• What’s the difference between SaaS and traditional on-site implementations?

• Will any of these alternative software models become the primary way that organisations buy software?

• How is today’s hosting model different to the ill-fated ASP model of the 1990s?

• Where does hosting fit in and how does it differ?

• What are the limitations of these software delivery models?

• Who are the leading vendors in this space? And is there a market leader yet?

For more information, kindly visit :
http://www.aarkstore.com/reports/The-Future-of-Software-Delivery-The-opportunities-and-challenges-of-emerging-software-delivery-models-13963.html

Negotiating the Emerging Biosimilars Landscape: Key Developments in the Regulatory Environment

As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011. With some of the earliest biopharmaceuticals having already lost patent protection, the originators of biopharmaceutical products are facing intense competition from generics developers. In response, originators are resorting to a range of defensive tactics, including the reformulation of existing products to improve efficacy, the implementation of more efficient delivery systems and the pursuit of high-level intellectual property (IP) battles.

‘Negotiating the Emerging Biosimilars Landscape’ is a new report published by Business Insights that examines the structure of the biopharmaceutical industry and the strategic approaches taken to alleviate the threat posed by the biosimilar market. The key factors affecting market access within the biosimilars market are assessed and the latest issues surrounding bioequivalence are examined. This report also provides a comprehensive review of the current legislative and regulatory positions of key geographic regions in addition to evaluating their anticipated future legislative changes and outcomes.

Key Findings

European Union guidelines have been prepared which authorise the use of specific therapeutic biopharmaceutical medicines as biosimilars. However, despite the range of current European guidelines produced by the EMEA, many European governments have issued laws prohibiting the automatic substitution of original products.

No approval pathway for biosimilars (FOB) exists in the USA, and one is unlikely to exist before 2010. A complex range of Acts and Bills have failed to resolve a number of outstanding legal and regulatory issues.

India’s biopharmaceutical industry is projected to grow to almost $5 billion by the end of 2010, representing annual growth in excess of 30%. However, despite WTO membership and recent advances in compliance with international regulatory/intellectual property laws, there remains no formal regulatory framework for biosimilars in India or China.

Health Canada has not yet publicly announced a legal or regulatory framework for biosimilar approval, and no legal framework for biosimilars currently exists in Japan. New regulatory frameworks and biosimilar guidelines are currently under development in both countries.

Use this report to…

• Identify and respond to the challenges and threats posed by the emergence of the biosimilars industry with this report’s examination of key trends and strategic approaches used by the biopharmaceutical industry to protect market share and intellectual property.
• Examine details of expired patents or impending patent expiries for first-gen biopharmaceuticals derived from recombinant DNA such as interferons, human insulin and insulin analogs, monoclonal antibodies (Mab) growth hormone and epoietins.
• Evaluate the legislative and regulatory requirements for biosimilars across key geographic regions including Europe, the US, Japan, Australia, Canada as well as the strategically important emerging markets of China and India.
• Assess the factors affecting biosimilar market access with this report’s analysis of the drivers and restraints to biosimilar approval, use and uptake, in addition to an investigation of the problems associated with determining bioequivalence.

Explore issues including…

Impending patent expiries. The critical challenge facing the biopharmaceutical industry is the expiry or pending expiry of patents for first generation biopharmaceuticals derived from recombinant DNA such as interferons, growth hormone and epoietins.

Defensive strategies. As part of efforts to protect the market share of products with impending patent expiries, originator biopharmaceutical companies have begun to protect intellectual property and engage in strategic alliances, joint ventures and mergers between themselves and major pharma companies.

Geographical disparities in biosimilar legislation. Different geographic regions have varying legislative approaches to the regulation and/or approval of biosimilars. Such discrepancies often lead to misunderstandings and can result in complexity and complication during the approval process.

Discover…

• Which biopharmaceutical companies are at risk from product patent expires?
• What is the status of the analytical techniques used for determining bioequivalence?
• What tactics prove most effective for originator biopharmaceutical companies who wish to protect their market position?
• What effect the market entry of second generation biopharmaceuticals by originator companies have on the biosimilars market?
• What are the growth drivers and restraints of the biosimilars market?
• How are global healthcare costs influenced by biosimilar market entry prospects?
• What is the current legislative and regulatory status of biosimilars in Europe and the US?
• How will China and India influence the biopharmaceutical and biosimilars market in the future?

For more information, kindly visit :
http://www.aarkstore.com/reports/Negotiating-the-Emerging-Biosimilars-Landscape-Key-Developments-in-the-Regulatory-Environment-13944.html

The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis – Aarkstore Enterprise

The Cardiovascular Market Outlook to 2013

The cardiovascular therapy area spans a range of treatment classes including anti-hypertensives, anti-dyslipidemics, anti-thrombotics, hematological preparations and cardiac therapies. Each sub-therapy area is facing a different set of issues and challenges, such as the current generic threat for dyslipidemics and competition from novel therapies in thrombosis. Leading products in these sub-therapy areas have proven to be significant growth drivers for Big Pharma, such as Pfizer’s Lipitor, Sanofi’s Plavix and Lovenox, and Amgen’s Aranesp. The recent emergence of smaller players and increased competition from generics has prompted leading players to engage in alliances and agreements for key drugs to keep pace with the changing market landscape.

‘The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis’ is a new report provides comprehensive coverage of every class of drugs across major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the 2007-13 period. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth.

Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report…

Some key findings from this report…

Anti-hypertensives were the highest selling sub-therapeutic category in 2007, with global sales of $52.9bn. Norvasc was the leading anti-hypertensive, with sales of $3.3bn.

The global market for anticoagulants will experience significant activity over the next two years with the introduction of new drugs including Boehringer Ingelheim’s Pradaxa/Rendix, Bayer- Schering/J&J’s Xarelto, BMS/Pfizer’s apixaban and Eli Lilly/Daiichi’s Effient.

Crestor has been steadily gaining market share and positive JUPITER trial results will help to further improve its market position. The positive trial data is likely to result in recommended cholesterol treatment goals becoming lowered, and Crestor will be well positioned to capture more patients and expand the market.

GlaxoSmithKline’s (GSK) acquisition of Reliant Pharma will contribute to GSK having the highest growth amongst the leading players through to 2013. The addition of key drugs such as Lovaza to GSK’s portfolio will drive this growth.

The anti-arrhythmic market is expected to remain a relatively small opportunity, as drug therapy has significant limitations. Multaq from Sanofi-Aventis may become the therapeutic standard in the first-line treatment of chronic atrial fibrillation.

Top five reasons to order your copy today

Assess patient potential, treatment trends and sales patterns across major cardiovascular diseases over the period 2007-13 within the subtherapy areas of hypertension, dyslipidemia, thrombosis and stroke.

Measure the market performance and strategic positioning of major pharmaceutical corporations with this report’s evaluation of the franchises and market shares of AstraZeneca, Amgen, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer and Sanofi-Aventis.

Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.

Compare the future prospects of key players and forecast sales of leading products across major indications to 2013 with this report’s analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and strategy/growth assessments.

Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

Leading cholesterol-lowering drugs show declining sales. Patent expirations have been off-setting positive drivers of growth including recent trial results that support aggressive LDL lowering in broader patient populations. The availability of generic simvastatin has resulted in increased therapeutic substitution and declining brand share.

Stalling growth of leading hypertension drugs. Angiotensin receptor blockers or ARBs have become the most prescribed antihypertensive class. However after several years of gaining market, growth in the branded ARB category appears to be stalling. A number of studies have shown ARBs to be no more effective than generic ACE inhibitors, most recently the ONTARGET study published in April, 2008

Novel oral anti-thrombotics threaten leading drugs. Novel drugs in the thrombosis market pipeline are expected to strongly compete with the current market leader Lovenox . The new drugs are orally formulated and are expected to substantially expand the market. Trial data has shown these drugs to be more efficacious without presenting a huge inrease in the risk of bleeding.

Your questions answered…

• Which indications will experience the greatest growth in the global cardiovascular market over the period 2008-13? • Which companies will become the key players in the cardiovascular area over the period 2009 -13?

How have recent major product launches from companies such as Gilead and Novartis performed?

What is the forecast market size and growth rate over the period 2008-2013 across the major cardiovascular indications?

Which pipeline products offer the highest growth potential? • What will be the competitive landscape of hypertension, dyslipidemia, thrombosis, hematology and cardiac therapies in 2013? 
 
For more information, kindly visit :
http://www.aarkstore.com/reports/The-Cardiovascular-Market-Outlook-to-2013-Competitive-landscape-global-market-analysis-and-pipeline-analysis-13941.html